Compare Altria Group Inc (MO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Zoetis Inc — how do they compare? Altria Group Inc trades at $68.15 (market cap $113.36B), while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Altria Group Inc is far larger — about 3.7× Zoetis Inc's market cap, and Altria Group Inc pays the higher dividend (6.54%). Which is the better fit depends on your goals.
| MO | ZTS | |
|---|---|---|
Market Cap | $113.36B | $30.29B |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $150.61 |
52-Week Low | $54.72 | $71.91 |
Enterprise Value | $135.57B | $37.86B |
Dividend Yield | 6.54% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MO trades at $68.18, down 1.02% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing revenue expectations, and maintains a strong 6.4% dividend yield after its 57th consecutive annual increase. Cash flow from operations remains robust at $9.29 billion for 2025, supporting dividend sustainability despite regulatory headwinds.
Outlook is cautiously optimistic with a consensus price target of $68.50, reflecting Wall Street's buy-heavy ratings. Key risks include ongoing FDA litigation, declining cigarette volumes, and high debt levels. The stock offers income appeal but faces secular challenges in the tobacco industry, requiring careful monitoring of regulatory developments and smoke-free segment growth.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
